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icant (p  0.14), a consistent beneficial effect was observed for all
components of the combined end point (MI, death, stroke), with
a significant reduction in the combined end point (2).
Dr. Eriksson also suggested that a potential negative effect of
bleeding on life expectancy should have been incorporated into the
model. Although bleeding may be associated with worse outcomes,
the extent to which bleeding independently increases the risk of
death (rather than being associated with other factors predictive of
death) has not been established. Given the low baseline rate of
bleeding in the CREDO trial, incorporating such an effect would
have a negligible impact on our results in any case.
Finally, Dr. Eriksson postulated that the low compliance rate in
the CREDO trial obscured the risk of bleeding. It is true that the
risk of bleeding in the CREDO trial may have been underesti-
mated because of the low compliance rate (62%). By the same
token, the benefits of treatment in the CREDO trial may also have
been underestimated. Compliance also affects the cost of therapy.
In the cost-effectiveness analysis, we adopted the conservative
approach of assigning to the treatment group the full cost of
clopidogrel (assuming full compliance), rather than the actual cost
of clopidogrel based on the observed compliance rate in the
CREDO trial.
In conclusion, we believe our analysis incorporates the best
available estimates of the clinical effectiveness of long-term clopi-
dogrel therapy. We look forward to the results of the Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) study, which should
further inform discussion regarding the value of long-term clopi-
dogrel therapy.
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